Clinical Trial Update: SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of SGN-30 (brentuximab vedotin) in combination with chemotherapy for relapsed or refractory Hodgkin lymphoma reported results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Hodgkin Lymphoma Lymphocyte-depleted
• Hodgkin Lymphoma Mixed Cellularity
• Hodgkin Lymphoma Nodular Lymphocyte Predominant
• Hodgkin Lymphoma Nodular Sclerosis
• Hodgkin Lymphoma Recurrent

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2015-02-23